Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
Construction of the plant will commence in 2025 with first production expected to be in 2027
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
This product will be manufactured at Lupin’s Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated
